| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2007, p. 3743-3749, Vol. 27, No. 10
0270-7306/07/$08.00+0 doi:10.1128/MCB.01561-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Center of Molecular and Human Genetics, Children's Research Institute, Columbus, Ohio 43205
Received 22 August 2006/ Returned for modification 22 September 2006/ Accepted 25 February 2007
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Although the hypothalamus consists of several cell types located in different regions, only a few transcription factors have been identified that are expressed in the developing hypothalamus. Brn-2 encodes a POU domain transcription factor, and its targeted mutation results in the loss of corticotropin-releasing hormone (CRH), vasopressin (AVP), and oxytocin (OT) in Brn-2-expressing cells. The homozygous mutant mice die in the neonatal period with a decrease in size and weight (18, 26). The basic helix-loop-helix (bHLH)-Per-Arnt-Sim transcription factor Sim1 is expressed in the paraventricular, the supraoptic, and the anterior periventricular nuclei. In Sim1 homozygous mutant mice, OT-, AVP-, thyrotropin-releasing hormone-, CRH-, and somatostatin (SS)-secreting neurons are absent in the Sim1-expressing regions (15). The Sim1 mutant mice die within 24 h after birth. Thus, the phenotype of Sim1 mutant mice overlaps with but is more severe than that of Brn-2 mutant mice. The Sim1 mutant hypothalamus fails to express Brn-2 during development, suggesting that a part of the phenotype of Sim1 mutant mice is due to loss of Brn-2 and that BRN-2 acts downstream of SIM1. Another bHLH-Per-Arnt-Sim transcription factor, Arnt-2, is also involved in hypothalamic development. Arnt-2 mutant mice show a strikingly similar phenotype to the Sim1-deficient mice, consistent with the finding that SIM1 and ARNT-2 form a heterodimer complex in vivo (8, 9, 14). Gsh-1 is a homeobox gene that is expressed in the developing hypothalamus and pituitary gland (32). Gsh-1 homozygous mutant mice exhibit marked dwarfism, infertility, and significant postnatal mortality due to the loss of growth hormone-releasing hormone (GHRH) expression in the arcuate nucleus (ARN) of the hypothalamus and decreased production of pituitary hormones, including growth hormone, thyrotropin, prolactin, adrenocorticotropin, and leutenizing hormone (12). Recently, it has been reported that a bHLH transcription factor, Mash1, is required for the expression of Gsh-1 and that loss of Mash1 results in an absence of GHRH expression (13). Otp encodes a homeodomain-containing transcription factor that is expressed in developing neurons, giving rise to the paraventricular, supraoptic, and anterior periventricular nuclei and ARN. Otp mutant mice die within 2 days after birth and fail to produce AVP, OT, thyrotropin-releasing hormone, CRH, and SS (1, 33).
Recently, a novel hypothalamic homeobox gene, Bsx/Bsx1a, was identified in vertebrates, including human, chicken, zebrafish, and frog (3). The expression of Bsx was detected in a broad region of the developing and postnatal hypothalamus, including the ARN and the dorsomedial nuclei. The Bsx-expressing area includes the neurons that express GHRH and SS, suggesting that BSX/BSX1A is involved in growth control. Thus, Bsx/Bsx1a likely plays a distinct role in hypothalamic development and/or function in comparison with the previously identified transcription factors described above. Since the molecular functions of BSX/BSX1A have not been characterized, here we report biochemical analyses of BSX/BSX1A and its isoform, BSX1B.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Antibody production and immunological analyses. Anti-BSX1A and anti-BSX1B sera were produced by immunizing rabbits with synthesized peptides, FPHPQ HAELP GKHCR and C-LRPGE KVRNP ALPVD, respectively (Genemed Synthesis). Antibodies were purified from the sera using a SulfoLink kit (PIERCE). pcDNA3-myc (vector), pcDNA3-myc-BSX1A, pcDNA3-myc-BSX1A mutant forms, and pcDNA3-myc-BSX1B were transfected into COS7 or Hs683 (human glioma cell line) cells using FuGENE6 (Roche). After 24 h, the cells were fixed in methanol and incubated with anti-BSX1A, anti-BSX1B, or anti-myc antibody (Sigma) as a primary antibody. The localization of the expressed proteins was visualized using Texas Red-conjugated anti-rabbit immunoglobulin G antibodies (Jackson ImmunoResearch) or fluorescein isothiocyanate-conjugated anti-mouse immunolobulin G antibodies (Sigma). To detect BSX1A and BSX1B in vivo, immunohistochemistry was performed on neonatal mouse brain sections using anti-BSX1A and anti-BSX1B sera (1:50; Zyagen).
Yeast reporter assay.
Yeast media and growth conditions were described previously (20, 22). A yeast expression vector, pAS2.1C, was used to express recombinant GAL4 DNA binding domain (GAL4DBD) fused to BSX1A, BSX1B, or their truncated forms. BSX1
C, BSX1
N, and BSX1B
C contained amino acid residues (aa) 1 to 135 and 169 to 232 of BSX1A and 1 to 101 of BSX1B, respectively. The transcriptional activities of the recombinant proteins were evaluated by ß-galactosidase (ß-Gal) activities and the growth of a Saccharomyces cerevisiae strain (Y190) on His-depleted medium as described previously (22).
Western analysis. Immunoblotting was performed using anti-GAL4DBD (Clontech) or anti-myc (Sigma) antibodies and Hybond-ECL membrane (Amersham) as described previously (22). 293T (a human embryonic kidney cell line) cells were used to check the mammalian expression plasmids (pcDNA3-myc-BSX1A, pcDNA3-myc-BSX1A mutant forms, and pcDNA3-myc-BSX1B).
Transcriptional reporter assay in mammalian cell lines.
To examine the transcriptional activities of BSX1A in mammalian cell lines, expression and reporter plasmids were transfected using FuGENE6 (Roche), and reporter luciferase activities were measured with a Dual-Luciferase Reporter Assay System (Promega) and a Veritas microplate luminometer (Turner Biosystems). The expression plasmids used were pcDNA3-myc (vector), pcDNA3-myc-BSX1A, pcDNA3-myc-BSX1A
C, pcDNA3-myc-BSX1A
AD, and pcDNA3-myc-BSX1A
NLS. BSX1A
AD contained aa 1 to 193 of BSX1A, and the arginine residues at positions 109 and 111 were replaced with glycine residues in BSX1A
NLS. A reporter plasmid was constructed by inserting annealed oligonucleotides (5'-GTACCCCAATTAGCGGATCCCAATTAGCAAGGGTTCCAATTAGCA-3' and 5'-GATCTGCTAATTGGAACCCTTGCTAATTGGGATCCGCTAATTGGG-3') into the KpnI/BglII sites of the pGL3-Promoter vector (Promega). Luciferase activities were normalized for transfection efficiency by cotransfecting the pRL-SV40 vector (Promega) and measuring Renilla luciferase activities. Hs683 and Neuro2a (a mouse neuroblastoma cell line) were used for the assay.
EMSA.
To investigate the DNA binding ability of BSX1A, we produced a glutathione S-transferase (GST) fusion protein (GST-BSX1A), its truncated forms (GST-BSX1A
C and GST-BSX1A
AD), and GST as described previously (22) and performed electrophoresis mobility shift assays (EMSA) using oligonucleotides that contained a consensus homeodomain binding site (ATTA). A radiolabeled BSX1A binding sequence (BBS) was prepared by annealing oligonucleotides, 5'-GATCCAATTAGC-3' and 5'-GATCGCTAATTG-3' and filling in recessed 3' ends using a Klenow fragment and [
-32P]dCTP. The radiolabeled probe and GST fusion proteins were incubated in the binding buffer [10 mM HEPES, pH 7.7, 50 mM KCl, 1 mM EDTA, 8% glycerol, 0.01 mg/ml poly(dI-dC)] in the presence or absence of BBS and/or mutated BBS (5'-GATCCATGTCTAGATC-3') as a competitor and separated in a 4% polyacrylamide gel by electrophoresis. The band intensity was measured using ImageQuant (GE Healthcare).
| RESULTS |
|---|
|
|
|---|
|
C was also located in the nuclei, indicating that the deleted C-terminal region is not necessary for the nuclear localization of BSX1A. However, myc-BSX1B was detected in the cytoplasm of transfected cells by both BSX1B and myc antibodies. This suggests that the N-terminal region of BSX1A does not contain a nuclear localization signal (NLS).
|
NLS) and examined the subcellular localization of BSX1A
NLS using Hs683 cells (Fig. 3). While the nuclear and cytoplasmic localizations of myc-BSX1A and myc-BSX1B were confirmed in Hs683, myc-BSX1A
NLS was detected in the cytoplasm, showing that 109RRRKAR114 is involved in the nuclear localization of BSX1A.
|
C), the band shift was not observed, suggesting that the homeodomain is involved in DNA binding.
|
C) in Y190. GAL4DBD-BSX1A
C did not show transcriptional activation activity, although a comparable amount of protein was detected by Western analysis. This suggests that the C region is essential for the transcriptional activity of BSX1A and contains a transcriptional activation domain. To confirm this, we fused the C region of BSX1A to GAL4DBD and tested the transcriptional activity. As expected, GAL4DBD-BSX1A
N showed positive ß-Gal activity, suggesting the C-terminal region is involved in the transcriptional activation of BSX1A.
|
|
AD) that lacked aa 194 to 232 and examined its DNA binding ability and transcriptional activity (Fig. 7). Although GST-BSX1A
AD retained DNA binding capability, myc-BSX1A
AD did not activate a reporter gene, indicating that the C-terminal region of BSX1A contains a transcriptional activation domain. myc-BSX1A
NLS also did not show reporter activation, which is likely due to the loss of DNA binding ability, since GST-BSX1A
NLS does not bind BBS.
|
| DISCUSSION |
|---|
|
|
|---|
|
Our studies of subcellular localization demonstrated that 109RRRKAR114 is an NLS of BSX1A. Arg-rich sequences are known to function as NLSs, since importin ß can mediate the nuclear transport of an Arg-rich sequence (23), suggesting that importin ß-mediated nuclear localization is a common mechanism to locate homeoproteins in the nuclei. Notably, BSX1A
NLS lost DNA binding ability, suggesting that 109RRRKAR114 is also important for homeodomain function. Therefore, importin ß may play an important role for the functional regulation of homeodomain-containing transcription factors.
Splice variants have been found in several homeobox genes, including Isl1, Lhx9, Pax6, Dmbx1, Prx1, Shox, Pitx2, and Csx1 (2, 6, 10, 21, 24, 25, 27, 29). The size of the transcriptome of homeobox genes seems to be larger than expected, and the regulation of transcription looks more complicated than expected. However, the physiological significance of the isoforms is still largely unknown. Functional domain mapping is one useful approach to investigate the functions of the isoforms. Unique features of BSX1B include its cytoplasmic localization and the lack of a homeodomain. A yeast two-hybrid assay determined that the N-terminal regions of BSX1A and BSX1B serve as protein interaction domains and that BSX1A and BSX1B bind a potential transcriptional regulator (our unpublished results), implying that BSX1B regulates the transcriptional activation of BSX1A by retaining its regulatory molecules in the cytoplasm. Collectively, our findings support the idea that the control of mRNA splicing is involved in hypothalamic development and/or functions.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Published ahead of print on 12 March 2007. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Ando, K., S. Shioda, H. Handa, and K. Kataoka. 2003. Isolation and characterization of an alternatively spliced variant of transcription factor Islet-1. J. Mol. Endocrinol. 31:419-425.[Abstract]
3. Cremona, M., E. Colombo, M. Andreazzoli, G. Cossu, and V. Broccoli. 2004. Bsx, an evolutionary conserved Brain Specific homeoboX gene expressed in the septum, epiphysis, mammillary bodies and arcuate nucleus. Gene Expr. Patterns 4:47-51.[CrossRef][Medline]
4. Dasen, J. S., and M. G. Rosenfeld. 1999. Combinational codes in signaling and synergy: lessons from pituitary development. Curr. Opin. Gen. Dev. 9:566-574.[CrossRef][Medline]
5. Dasen, J. S., and M. G. Rosenfeld. 1999. Signaling mechanisms in pituitary morphogenesis and cell fate determination. Curr. Opin. Cell Biol. 11:669-677.[CrossRef][Medline]
6. Failli, V., M. Rogard, M. Mattei, P. Vernier, and S. Retaux. 2000. Lhx9 and Lhx9a LIM-homeodomain factors: genomic structure, expression patterns, chromosomal localization, and phylogenetic analysis. Genomics 64:307-317.[CrossRef][Medline]
7. Givens, M. L., N. Rave-Harel, V. D. Goonewardena, R. Kurotani, S. E. Berdy, C. H. Swan, J. L. Rubenstein, B. Robert, and P. L. Mellon. 2005. Developmental regulation of gonadtropin-releasing hormone gene expression by the MSX and DLX homeodomain protein families. J. Biol. Chem. 280:19156-19165.
8. Hosoya, T., Y. Oda, S. Takahashi, M. Morita, S. Kawauchi, M. Ema, M. Yamamoto, and Y. Fujii-Kuriyama. 2001. Defective development of secretory neurons in the hypothalamus of Arnt2-knockout mice. Genes Cells 6:361-374.[Abstract]
9. Keith, B., D. M. Adelman, and M. C. Simon. 2001. Targeted mutation of the murine arylhydrocarbon receptor nuclear translocator 2 (Arnt2) gene reveals redundancy with Arnt. Proc. Natl. Acad. Sci. USA 98:6693-6697.
10. Kim, J., and J. D. Lauderdale. 2006. Analysis of Pax6 expression using a BAC transgenic reveals the presence of a paired-less isoform of Pax6 in the eye. Dev. Biol. 292:486-505.[CrossRef][Medline]
11. Kurtzman, A. L., and N. Schechter. 2001. Ubc9 interacts with a nuclear localization signal and mediates nuclear localization of the paired-like homeobox protein Vsx-1 independent of SUMO-1 modification. Proc. Natl. Acad. Sci. USA 98:5602-5607.
12. Li, H., P. S. Zeitler, M. T. Valerius, K. Small, and S. S. Potter. 1996. Gsh-1, an orphan Hox gene, is required for normal pituitary development. EMBO J. 15:714-724.[Medline]
13. McNay, D. E. G., M. Pelling, S. Claxton, F. Guillemot, and S.-L. Ang. 2006. Mash1 is required for genetic and subtype differentiation of hypothalamic neuroendocrine cells. Mol. Endocrinol. 20:1623-1632.
14. Michaud, J. L., C. DeRossi, N. R. May, B. C. Holdener, and C. Fan. 2000. Arnt2 acts as the dimerization partner of Sim1 for the development of the hypothalamus. Mech. Dev. 90:253-261.[CrossRef][Medline]
15. Michaud, J. L., T. Rosenquist, N. R. May, and C. Fan. 1998. Development of neuroendocrine lineages requires the bHLH-PAS transcription factor Sim1. Genes Dev. 12:3264-3275.
16. Mullis, P. E. 2000. Transcriptional factors in pituitary gland development and their clinical impact on phenotype. Hormone Res. 54:107-119.[CrossRef][Medline]
17. Mutsuga, N., Y. Iwasaki, M. Morishita, A. Nomura, E. Yamamori, M. Yoshida, M. Asai, N. Ozaki, F. Kambe, H. Seo, Y. Oiso, and H. Saito. 2001. Homeobox protein Gsh-1-dependent regulation of the rat GHRH gene promoter. Mol. Endocrinol. 15:2149-2156.
18. Nakai, S., H. Kawano, T. Yudate, M. Nishi, J. Kuno, A. Nagata, K. Jishage, H. Hamada, H. Fujii, K. Kawamura, K. Shiba, and T. Noda. 1995. The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineage in the hypothalamus of the mouse. Genes Dev. 9:3109-3121.
19. Nishijima, I., and A. Ohtoshi. 2006. Characterization of a novel prospero-related homeobox gene, Prox2. Mol. Genet. Genomics 275:471-478.[CrossRef][Medline]
20. Ohtoshi, A., K. Arai, and H. Masai. 1998. Two recessive modes of growth inhibition by exogenously introduced mutant genes: analysis of mutant CDC28 and CDC7 genes in Sacchromyces cerevisiae. J. Biochem. Mol. Biol. Biophys. 1:253-263.
21. Ohtoshi, A., I. Nishijima, M. J. Justice, and R. R. Behringer. 2002. Dmbx1, a novel evolutionarily conserved paired-like homeobox gene expressed in the brain of mouse embryos. Mech. Dev. 110:241-244.[CrossRef][Medline]
22. Ohtoshi, A., and H. Otoshi. 2001. Analysis of ß3-endonexin mutants for their ability to interact with cyclin A. Mol. Genet. Genomics 266:664-671.[CrossRef][Medline]
23. Palmeri, D., and M. H. Malim. 1999. Importin beta can mediate the nuclear import of an arginine-rich nuclear localization signal in the absence of importin alpha. Mol. Cell. Biol. 19:1218-1225.
24. Peterson, R. E., S. Hoffman, and M. J. Kern. 2005. Opposing roles of two isoforms of the Prx1 homeobox gene in the chondrogenesis. Dev. Dyn. 233:811-821.[CrossRef][Medline]
25. Rao, E., R. J. Blaschke, A. Marchini, B. Niesler, M. Burnett, and G. A. Rappold. 2001. The Leri-Weill and Turner syndrome homeobox gene SHOX encodes a cell-type specific transcriptional activator. Hum. Mol. Genet. 10:3083-3091.
26. Schonemann, M. D., A. K. Ryan, R. J. McEvilly, S. M. O'Connell, C. A. Arias, K. A. Kalla, P. Li, P. E. Sawchenko, and M. G. Rosenfeld. 1995. Development and survival of the endocrine hypothalamus and pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev. 9:3122-3135.
27. Schweickert, A., H. Steinbeisser, and M. Blum. 2001. Differential gene expression of Xenopus Pitx1, Pitx2b and Pitx2c during cement gland, stomodeum and pituitary development. Mech. Dev. 107:191-194.[CrossRef][Medline]
28. Scully, K. M., and M. G. Rosenfeld. 2002. Pituitary development: regulatory codes in mammalian organogenesis. Science 295:2231-2235.
29. Shiojima, I., I. Komuro, T. Mizuno, R. Aikawa, H. Akazawa, T. Oka, T. Yamazaki, and Y. Yazaki. 1996. Molecular cloning and characterization of human cardiac homeobox gene CSX1. Circ. Res. 79:920-929.
30. Stepchenko, A., and M. Nirenberg. 2004. Mapping activation and repression domains of the vnd/NK-2 homeodomain protein. Proc. Natl. Acad. Sci. USA 101:13180-13185.
31. Treier, M., and M. G. Rosenfeld. 1996. The hypothalamic-pituitary axis: co-development of two organs. Curr. Opin. Cell Biol. 8:833-843.[CrossRef][Medline]
32. Valerius, M. T., H. Li, J. L. Stock, M. Weinstein, S. Kaur, G. Singh, and S. S. Potter. 1995. Gsh-1: a novel murine homeobox gene expressed in the central nervous system. Dev. Dyn. 203:337-351.[Medline]
33. Wang, W., and T. Lufkin. 2000. The murine Otp homeobox gene plays an essential role in the specification of neuronal cell lineages in the developing hypothalamus. Dev. Biol. 227:432-449.[CrossRef][Medline]
34. Zhang, Y. A., A. Okada, C. H. Lew, and S. K. McConnell. 2002. Regulated nuclear trafficking of the homeodomain protein otx1 in cortical neurons. Mol. Cell Neurosci. 19:430-446.[CrossRef][Medline]
35. Zhu, X., C. R. Lin, G. G. Prefontaine, J. Tollkuhn, and M. G. Rosenfeld. 2005. Genetic control of pituitary development and hypopituitarism. Curr. Opin. Genet. Dev. 15:332-340.[CrossRef][Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|